Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound, empagliflozin in various diabetes subpopulations

Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound, empagliflozin in various diabetes subpopulations
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news